Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| CHOL | CHOLERA (VAXCHORA) | PAXVAX | UNK | Unknown | PO / MO |
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
patient took Vivotif and Vaxchora together; Case reference number US-BN-2025-001333 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV25-1867) on 30-Jul-2025 and concerns an 18-year-old male patient. The patient's medical history and concomitant medications were not provided. On 30-Jul-2025, the patient took together the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for the indication typhoid immunization and Vaxchora (batch number: unknown) at an unknown dose, orally, for an unknown indication (explicitly coded as 'product administration error') At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif and Vaxchora vaccine. Additional information received from pharmacist via Communications (reference number: USBAV25-1868) on 30-Jul-2025 included: dosing information for Vaxchora vaccine and additional reference number.; Reporter's Comments: An 18-year-old male patient took together the first dose of Vivotif for the indication typhoid immunization and Vaxchora for an unknown indication, which is considered as product administration error. It was unknown if the patient experienced any adverse events due to Vivotif and Vaxchora vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Product administration error is not related to the suspect vaccines, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient took together the first dose of Vivotif for the indication typhoid immunization and Vaxchora for an unknown indication, which is considered as product administration error. It was unknown if the patient experienced any adverse events due to Vivotif and Vaxchora vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Product administration error is not related to the suspect vaccines, but to a human factor. This case is considered as non-serious.
Comments: None